Transcriptomic analysis within the tumor revealed the upregulation of genes encoding medium-sized neurofilament (NEFM) and ryanodine receptor type 3 (RYR3), which share sequence similarities with major antigenic targets implicated in myasthenia gravis, such as acetylcholine receptor (AChR), titin, and ryanodine receptor type 1 and 2 (RYR1, RYR2). Here, RYR1 is linked to neoplasm.